Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 224 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Epilepsy, Partial Clear all
Completed Phase 3 Interventional Results available

Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures

NCT00464269
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam 2.5 mg, Brivaracetam 10 mg, Brivaracetam 25 mg
Other · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 23, 2026, 12:24 AM EDT
Completed Phase 3 Interventional Results available

Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures

NCT00655551
View directory record Official record
Conditions
Partial Epilepsies, Partial Onset Seizures
Interventions
lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Phoenix, Arizona • Baltimore, Maryland • Chesterfield, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 23, 2026, 12:24 AM EDT
Completed Not applicable Interventional

Stimulation of the Thalamus for Arousal Restoral in Temporal Lobe Epilepsy

NCT04897776
View directory record Official record
Conditions
Epilepsy, Temporal Lobe
Interventions
Central Thalamic Stimulation, Hippocampal Stimulation
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
New Haven, Connecticut • Rochester, Minnesota • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 23, 2026, 12:24 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Language and Emotional Function in Patients With Temporal Lobe Epilepsy

NCT00081432
View directory record Official record
Conditions
Epilepsy, Temporal Lobe
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 12:24 AM EDT
Recruiting Not applicable Interventional

Breathing Rescue for SUDEP Prevention

NCT05981755
View directory record Official record
Conditions
Focal Epilepsy
Interventions
Breathing tasks, Brain mapping with stimulation
Other · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 23, 2026, 12:24 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Localizing Epileptic Networks Using MRI and iEEG

NCT04649008
View directory record Official record
Conditions
Epilepsy, Epilepsy Intractable, Epilepsy, Temporal Lobe
Interventions
3T Magnetic Resonance Imaging, Intracranial electroencephalography recordings, 7T Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 23, 2026, 12:24 AM EDT
Terminated Phase 3 Interventional Results available

Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)

NCT01891890
View directory record Official record
Conditions
Epilepsy, Partial, Epilepsy, Localization Related
Interventions
Oxcarbazepine, Levetiracetam, Lamotrigine
Drug
Lead sponsor
Emory University
Other
Eligibility
5 Years to 16 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
Little Rock, Arkansas • San Diego, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 23, 2026, 12:24 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

NCT00655486
View directory record Official record
Conditions
Partial Epilepsies, Partial Onset Seizures
Interventions
lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Baltimore, Maryland • Chesterfield, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 23, 2026, 12:24 AM EDT
Completed Phase 3 Interventional

A Placebo-controlled Study of Levetiracetam In Children (1mo to 4yrs of Age) With Partial Onset Seizures.

NCT00175890
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
Levetiracetam, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
1 Month to 4 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 23, 2026, 12:24 AM EDT
Terminated Phase 4 Interventional

Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.

NCT02727101
View directory record Official record
Conditions
Epilepsy
Interventions
perampanel
Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 23, 2026, 12:24 AM EDT
Not yet recruiting Phase 4 Interventional

Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures

NCT06534502
View directory record Official record
Conditions
Seizures, Seizures, Focal, Seizure, Partial Onset, Seizure Disorder, Partial, Seizure, Partial, Epilepsies, Partial, Epilepsy
Interventions
Zonisamide Oral Product
Drug
Lead sponsor
Azurity Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 12:24 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test the Efficacy, Safety, and Pharmacokinetics of Rozanolixizumab in Adult Study Participants With Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis

NCT04875975
View directory record Official record
Conditions
Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Interventions
Rozanolixizumab, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 89 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Aurora, Colorado • Jacksonville, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 23, 2026, 12:24 AM EDT
Not listed Not applicable Interventional

Detecting PNES With Single-channel sEMG

NCT03313362
View directory record Official record
Conditions
Epilepsy, Motor Partial, Psychogenic Seizures
Interventions
SPEAC System, video EEG
Device
Lead sponsor
Brain Sentinel
Other
Eligibility
22 Years to 99 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Durham, North Carolina • Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 23, 2026, 12:24 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)

NCT01278173
View directory record Official record
Conditions
Adult Refractory Complex Partial Seizures
Interventions
Sabril
Drug
Lead sponsor
Lundbeck LLC
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
22
States / cities
San Francisco, California • New Haven, Connecticut • Dover, Delaware + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 23, 2026, 12:24 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic

NCT01091662
View directory record Official record
Conditions
Epilepsy
Interventions
Eslicarbazepine acetate 1600 mg, Eslicarbazepine acetate 1200 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
39
States / cities
Tucson, Arizona • Conway, Arkansas • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 23, 2026, 12:24 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

NCT02914314
View directory record Official record
Conditions
Epilepsy
Interventions
perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
1 Month to 4 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
17
States / cities
Los Angeles, California • Gulf Breeze, Florida • Loxahatchee Groves, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 23, 2026, 12:24 AM EDT
Terminated Phase 4 Interventional Results available

An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

NCT01607346
View directory record Official record
Conditions
Epilepsy
Interventions
ezogabine/retigabine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Bethesda, Maryland • Columbus, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 23, 2026, 12:24 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Controlled Trial of Ganaxolone in Adult Uncontrolled Partial-Onset Seizures

NCT00465517
View directory record Official record
Conditions
Partial Epilepsy, Catamenial Epilepsy
Interventions
Ganaxolone, Placebo
Drug · Other
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 23, 2026, 12:24 AM EDT
Completed Not applicable Interventional Results available

Treating Deep Seizure Foci With Noninvasive Surface Brain Stimulation

NCT02339376
View directory record Official record
Conditions
Epilepsy, Temporal Lobe
Interventions
Low-frequency repetitive transcranial magnetic stimulation, High-frequency repetitive transcranial magnetic stimulation, Sham repetitive transcranial magnetic stimulation
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 23, 2026, 12:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures

NCT00988429
View directory record Official record
Conditions
Partial Epilepsy
Interventions
800 mg QD Eslicarbazepine acetate, 1200 mg QD Eslicarbazepine acetate, Placebo
Drug
Lead sponsor
Bial - Portela C S.A.
Industry
Eligibility
16 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
106
States / cities
Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 23, 2026, 12:24 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database

NCT02107989
View directory record Official record
Conditions
Epilepsy
Interventions
MRI, MEG
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
8 Years to 120 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 12:24 AM EDT
Recruiting Early Phase 1 Interventional

Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables

NCT07012148
View directory record Official record
Conditions
Focal Epilepsy, Generalized Seizure, Drug Refractory Epilepsy
Interventions
UNEEG SubQ device, seizure forecasts, nasal diazepam, Preventative Medication (PM)
Device · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 12:24 AM EDT
Completed Phase 3 Interventional Results available

Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial Seizures

NCT00334958
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Rufinamide
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
77
States / cities
Mobile, Alabama • Northport, Alabama • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 23, 2026, 12:24 AM EDT
Withdrawn No phase listed Observational

Biomarkers in Neurodegenerative Diseases

NCT04055532
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer Disease (AD), Dementia With Lewy Bodies (DLB), Frontotemporal Lobar Degeneration (FTLD), Parkinsons Disease With Dementia (PDD), Transient Epileptic Amnesia (TEA), Temporal Lobe Epilepsy (TLE), Spinocerebellar Ataxias (SCA), HIV Associated Neurocognitive Disorder (HAND), Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS)
Interventions
Neuraceq
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Timeline
2019 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 23, 2026, 12:24 AM EDT